Cargando…

Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study

Arterial thromboembolism has been associated with cancer or its treatment. Unlike venous thromboembolism, the incidence and risk factors have not been extensively studied. Here, we investigated the incidence of arterial thromboembolic events (ATEs) in an institutional series of advanced urinary trac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamias, Aristotelis, Tzannis, Kimon, Zakopoulou, Roubini, Sakellakis, Minas, Dimitriadis, John, Papatheodoridi, Alkistis, Rallidis, Loukianos, Halvatsiotis, Panagiotis, Tsiara, Anna, Kaparelou, Maria, Kostouros, Efthymios, Barbarousi, Despina, Koutsoukos, Konstantinos, Fragiadis, Evangelos, Dellis, Athanasios E., Anastasiou, Ioannis, Stravodimos, Konstantinos, Pinitas, Alexandros, Papatsoris, Athanasios, Adamakis, Ioannis, Varkarakis, Ioannis, Fragoulis, Charalampos, Pagoni, Stamatina, Matsouka, Charis, Skolarikos, Andreas, Mitropoulos, Dionysios, Doumas, Konstantinos, Deliveliotis, Charalampos, Constantinides, Constantinos, Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498031/
https://www.ncbi.nlm.nih.gov/pubmed/36135047
http://dx.doi.org/10.3390/curroncol29090478
_version_ 1784794655093686272
author Bamias, Aristotelis
Tzannis, Kimon
Zakopoulou, Roubini
Sakellakis, Minas
Dimitriadis, John
Papatheodoridi, Alkistis
Rallidis, Loukianos
Halvatsiotis, Panagiotis
Tsiara, Anna
Kaparelou, Maria
Kostouros, Efthymios
Barbarousi, Despina
Koutsoukos, Konstantinos
Fragiadis, Evangelos
Dellis, Athanasios E.
Anastasiou, Ioannis
Stravodimos, Konstantinos
Pinitas, Alexandros
Papatsoris, Athanasios
Adamakis, Ioannis
Varkarakis, Ioannis
Fragoulis, Charalampos
Pagoni, Stamatina
Matsouka, Charis
Skolarikos, Andreas
Mitropoulos, Dionysios
Doumas, Konstantinos
Deliveliotis, Charalampos
Constantinides, Constantinos
Dimopoulos, Meletios-Athanasios
author_facet Bamias, Aristotelis
Tzannis, Kimon
Zakopoulou, Roubini
Sakellakis, Minas
Dimitriadis, John
Papatheodoridi, Alkistis
Rallidis, Loukianos
Halvatsiotis, Panagiotis
Tsiara, Anna
Kaparelou, Maria
Kostouros, Efthymios
Barbarousi, Despina
Koutsoukos, Konstantinos
Fragiadis, Evangelos
Dellis, Athanasios E.
Anastasiou, Ioannis
Stravodimos, Konstantinos
Pinitas, Alexandros
Papatsoris, Athanasios
Adamakis, Ioannis
Varkarakis, Ioannis
Fragoulis, Charalampos
Pagoni, Stamatina
Matsouka, Charis
Skolarikos, Andreas
Mitropoulos, Dionysios
Doumas, Konstantinos
Deliveliotis, Charalampos
Constantinides, Constantinos
Dimopoulos, Meletios-Athanasios
author_sort Bamias, Aristotelis
collection PubMed
description Arterial thromboembolism has been associated with cancer or its treatment. Unlike venous thromboembolism, the incidence and risk factors have not been extensively studied. Here, we investigated the incidence of arterial thromboembolic events (ATEs) in an institutional series of advanced urinary tract cancer (aUTC) treated with cytotoxic chemotherapy. The ATE definition included peripheral arterial embolism/thrombosis, ischemic stroke and coronary events. A total of 354 aUTC patients were analyzed. Most patients (95.2%) received platinum-based chemotherapy. A total of 12 patients (3.4%) suffered an ATE within a median time of 3.6 months from the start of chemotherapy. The most frequent ATE was ischemic stroke (n = 7). Two ATEs were fatal. The 6-month and 24-month incidence were 2.1% (95% confidence interval [CI]: 0.9–4.1) and 3.6% (95% CI: 1.9–6.2), respectively. Perioperative chemotherapy increased the risk for ATE by 5.55-fold. Tumors other than UTC and pure non-transitional cell carcinoma histology were also independent risk factors. No association with the type of chemotherapy was found. Overall, ATEs occur in 4.6% of aUTC patients treated with chemotherapy and represent a clinically relevant manifestation. Perioperative chemotherapy significantly increases the risk for ATE. The role of prophylaxis in high-risk groups should be prospectively studied.
format Online
Article
Text
id pubmed-9498031
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94980312022-09-23 Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study Bamias, Aristotelis Tzannis, Kimon Zakopoulou, Roubini Sakellakis, Minas Dimitriadis, John Papatheodoridi, Alkistis Rallidis, Loukianos Halvatsiotis, Panagiotis Tsiara, Anna Kaparelou, Maria Kostouros, Efthymios Barbarousi, Despina Koutsoukos, Konstantinos Fragiadis, Evangelos Dellis, Athanasios E. Anastasiou, Ioannis Stravodimos, Konstantinos Pinitas, Alexandros Papatsoris, Athanasios Adamakis, Ioannis Varkarakis, Ioannis Fragoulis, Charalampos Pagoni, Stamatina Matsouka, Charis Skolarikos, Andreas Mitropoulos, Dionysios Doumas, Konstantinos Deliveliotis, Charalampos Constantinides, Constantinos Dimopoulos, Meletios-Athanasios Curr Oncol Article Arterial thromboembolism has been associated with cancer or its treatment. Unlike venous thromboembolism, the incidence and risk factors have not been extensively studied. Here, we investigated the incidence of arterial thromboembolic events (ATEs) in an institutional series of advanced urinary tract cancer (aUTC) treated with cytotoxic chemotherapy. The ATE definition included peripheral arterial embolism/thrombosis, ischemic stroke and coronary events. A total of 354 aUTC patients were analyzed. Most patients (95.2%) received platinum-based chemotherapy. A total of 12 patients (3.4%) suffered an ATE within a median time of 3.6 months from the start of chemotherapy. The most frequent ATE was ischemic stroke (n = 7). Two ATEs were fatal. The 6-month and 24-month incidence were 2.1% (95% confidence interval [CI]: 0.9–4.1) and 3.6% (95% CI: 1.9–6.2), respectively. Perioperative chemotherapy increased the risk for ATE by 5.55-fold. Tumors other than UTC and pure non-transitional cell carcinoma histology were also independent risk factors. No association with the type of chemotherapy was found. Overall, ATEs occur in 4.6% of aUTC patients treated with chemotherapy and represent a clinically relevant manifestation. Perioperative chemotherapy significantly increases the risk for ATE. The role of prophylaxis in high-risk groups should be prospectively studied. MDPI 2022-08-24 /pmc/articles/PMC9498031/ /pubmed/36135047 http://dx.doi.org/10.3390/curroncol29090478 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bamias, Aristotelis
Tzannis, Kimon
Zakopoulou, Roubini
Sakellakis, Minas
Dimitriadis, John
Papatheodoridi, Alkistis
Rallidis, Loukianos
Halvatsiotis, Panagiotis
Tsiara, Anna
Kaparelou, Maria
Kostouros, Efthymios
Barbarousi, Despina
Koutsoukos, Konstantinos
Fragiadis, Evangelos
Dellis, Athanasios E.
Anastasiou, Ioannis
Stravodimos, Konstantinos
Pinitas, Alexandros
Papatsoris, Athanasios
Adamakis, Ioannis
Varkarakis, Ioannis
Fragoulis, Charalampos
Pagoni, Stamatina
Matsouka, Charis
Skolarikos, Andreas
Mitropoulos, Dionysios
Doumas, Konstantinos
Deliveliotis, Charalampos
Constantinides, Constantinos
Dimopoulos, Meletios-Athanasios
Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
title Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
title_full Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
title_fullStr Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
title_full_unstemmed Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
title_short Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
title_sort risk for arterial thromboembolic events (ates) in patients with advanced urinary tract cancer (autc) treated with first-line chemotherapy: single-center, observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498031/
https://www.ncbi.nlm.nih.gov/pubmed/36135047
http://dx.doi.org/10.3390/curroncol29090478
work_keys_str_mv AT bamiasaristotelis riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT tzanniskimon riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT zakopoulouroubini riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT sakellakisminas riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT dimitriadisjohn riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT papatheodoridialkistis riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT rallidisloukianos riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT halvatsiotispanagiotis riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT tsiaraanna riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT kapareloumaria riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT kostourosefthymios riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT barbarousidespina riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT koutsoukoskonstantinos riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT fragiadisevangelos riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT dellisathanasiose riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT anastasiouioannis riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT stravodimoskonstantinos riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT pinitasalexandros riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT papatsorisathanasios riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT adamakisioannis riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT varkarakisioannis riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT fragoulischaralampos riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT pagonistamatina riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT matsoukacharis riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT skolarikosandreas riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT mitropoulosdionysios riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT doumaskonstantinos riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT deliveliotischaralampos riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT constantinidesconstantinos riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy
AT dimopoulosmeletiosathanasios riskforarterialthromboemboliceventsatesinpatientswithadvancedurinarytractcancerautctreatedwithfirstlinechemotherapysinglecenterobservationalstudy